Drug Trial Radar · NCT06628206
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Dec 15, 2024
Primary completion
Nov 15, 2026
Study completion Feb 15, 2027
Sponsor
- Lead sponsor
- LAPIX Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to study the drug LPX-TI641 in patients with rheumatoid arthritis and psoriatic arthritis. We will compare the safety and tolerability of LPX-TI641 to placebo that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Conditions
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
Interventions
LPX-TI641Drug
Oral administration QD for 28 consecutive days
PlaceboDrug
Drug is LPX-TI641. Placebo an identical formulation without the LPX-TI641.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with RA and PsA.Time frame: 56 days
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Universal Medical Center
Homestead, Florida
Regenerate Primary Medical Research
South Miami, Florida
Red River Research Partners
Fargo, North Dakota
Altoona Center for Clinical Research
Altoona, Pennsylvania
Clinical Investigations of Texas
Plano, Texas
Triumpharma Clinical Research Unit at AlEssra Hospital
Amman, Jordan, Jordan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.